This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
With new platforms, tools, privacy regulations, and patient behaviors evolving every week, teams that fail to adapt risk falling behind. Patients are now proactive participants in their treatment decisions, digital engagement is exploding, and regulatory pressures are increasing.
This fuels an enormous need for effective patient communication and education as new therapies move through the biopharma pipeline. Marketing to rare disease patient populations is equal parts opportunity and responsibility. audiences (direct-to-patient advertising rules are fundamentally different overseas).
Maximizing Patient Safety and Sustaining Long Term Quality Through Enhanced Device Surveillance while navigating the EU Regulatory Landscape. For more information please contact: Ria Kiayia, DigitalMedia and PR Marketing Executive at riak@marcusevanscy.com or visit: [link]. REGISTER TODAY.
However, internal media teams also include several challenges, starting with a need for significant investments to hire and train individuals on the corporate infrastructure. This can be cost-effective as well, based on the media team and the platforms utilized to promote the brands.
In this challenging environment, marketers need to rise above the clutter by embracing data-driven marketing as the means to better target their audiences, provide an optimal customer experience, and drive crucial new patient start volumes as a result. Improving Efficiencies and Outcomes Through Continuous Optimization.
The topics focused on the emerging technologies that pharma is implementing to enhance customer experiences for patients, payers, and HCPs. During the summit, speakers shared their thoughts and opinions on new technologies, how to prioritize customer experiences during COVID-19, and their digital strategies.
I hated the term networking. College professors are real big on that like, “You got to network. Wouldn’t you know that through that, all of that school and everything else, when I graduated, the most important thing in my life became not what I knew or the degrees I had, but who I knew, who I had networked with.
The cookie’s death can lead to a better future for digitalmedia globally, ” says Dennis Buchheim, EVP and General Manager, IAB Tech Lab. However, for pharma brands, CRM programs including email or text have proven value with current patients, particularly around adherence. appeared first on Pharma Marketing Network.
One lasting effect we see for pharma is the their “Digital Transformation” which was accelerated due to COVID, is here to stay and is not likely to unwind any time soon – in fact continues to accelerate. What does that do to the doctor patient visit? A Continued Boost in Pharma’s Reputation.
RJ Lewis (EHS): Hello, this is RJ Lewis from Pharma Marketing Network. He’s the Chief Digital Officer for Health at Ogilvy. And he’s also a Pharma Marketing Network Editorial Advisory Board member. You let the machine go find the right patients. I’ll be your host today. He’s known industry-wide.
RJ Lewis (EHS): Hello, this is RJ Lewis from Pharma Marketing Network. He’s the Chief Digital Officer for Health at Ogilvy. And he’s also a Pharma Marketing Network Editorial Advisory Board member. You let the machine go find the right patients. I’ll be your host today. He’s known industry-wide.
RJ (PMN): Yeah yeah wow you got a lot of great points there and just a tight some of that back to Pharma it’s interesting you know the idea of a persona is so powerful you know as suppose to talking about someone as a consumer or in our case many times we refer to them as a patient and I can’t tell you how many times I’ve listened (..)
Bayer, where I was the Executive Director of DigitalMedia Strategy and Operations was the top brand. I felt outraged when a white team member said people need to be patient. Making DE&I More Actionable Had I not hired my team from my network, I could have gone months without interacting with Black people.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content